Biogen Message Board - Msg: 4353317

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 175.32

+4.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jonas Grumby who wrote (649)	5/6/1998 5:07:00 PM
From: Harold Engstrom	Read Replies (1) of 1686

After the market... CAMBRIDGE, Mass., May 6 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today said it was pleased by a jury's verdict in the U.S. District Court for the District of Massachusetts rejecting all claims made by a class of plaintiffs against the company relating to Biogen's 1994 public comments on HIRULOG(R)(bivalirudin) direct thrombin inhibitor. Jim Vincent, Biogen's Chairman, said, "This abusive lawsuit is typical of the kind of suit targeted by recent Congressional reform legislation, and underscores the need for further reform in this area of our legal system such as the legislation that is currently pending before Congress. "As expected, the jury recognized that Biogen's statements were truthful, complete and timely. In our 20-year history, we had never before had a shareholder suit and we are pleased to retain our unblemished record of accuracy and honesty. We will now put this matter behind us and continue our mission of developing life-saving and life-improving drugs."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next